The Sputnik V vaccine is efficient against new COVID strains, a research published in the Vaccines leading international magazine by the Gamaleya National Research Center for Epidemiology and Microbiology has shown, the Russian Direct Investment Fund (RDIF) said on Monday.
The research indicates that Sputnik V retains its antimicrobial capabilities against the new pathogens, TASS reports.
According to the announcement, Sputnik V showed substantially less of a loss in its virus neutralizing activity against a number of variations when compared to data from other vaccine manufacturers who had previously validated the effectiveness of their vaccines against new coronavirus variants.
The Gamaleya Center has been aggressively investigating new SARS-CoV-2 strains in order to evaluate the effectiveness of the Sputnik V vaccination as they continue to develop in various regions of the world, according to the RDIF. The Center and the Foundation are also contemplating collaborating with other top companies to build “vaccine cocktails” based on the first component of the Sputnik V injection.